Businesswire  | 
aufrufe Aufrufe: 69

BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2026

play Anhören
share Teilen
feedback Feedback
copy Kopieren
newsletter
font_big Schrift vergrößern
Wirtschaftsnachrichten (Symbolbild)
Quelle: - ©unsplash.com:
Bioqual -   Bioqual Chart 0,00%
Zugehörige Wertpapiere:

BIOQUAL, Inc. (Pink Limited:BIOQ):

Nine Months Ended

Three Months Ended

 

February 28,

February 28,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Revenue

30,677,988

 

37,198,902

 

9,843,148

 

14,032,982

 
 

(Loss) Income Before Income Tax

(1,570,941

(1,312,897

(1,038,024

1,291,330

 
 

Net (Loss) Income

(1,138,641

(951,497

(752,524

936,030

 
 

Basic Earnings per Share

 

of Common Stock

(1.27

(1.06

(0.84

1.05

 
 

Diluted Earnings per Share

 

of Common Stock

(1.27

(1.06

(0.84

1.05

 
 

Weighted Average

 

Number of Shares Outstanding

 

 

 

For Basic Earnings Per Share

 

894,416

 

 

894,416

 

 

894,416

 

 

894,416

 
 

Weighted Average

 

Number of Shares Outstanding

 

For Diluted Earnings Per Share

 

893,926

 

 

894,394

 

 

893,858

 

 

894,383

 

For more detail related to the fiscal year 2026 unaudited third quarter results, please visit our web site at www.bioqual.com.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government and commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260421934317/en/

Für dich aus unserer Redaktion zusammengestellt

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Weitere Artikel des Autors

Themen im Trend